Amgen Inc. $AMGN Shares Purchased by Czech National Bank

Czech National Bank raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 3.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 142,002 shares of the medical research company’s stock after purchasing an additional 5,269 shares during the period. Czech National Bank’s holdings in Amgen were worth $46,479,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of AMGN. Board of the Pension Protection Fund acquired a new position in shares of Amgen in the 4th quarter valued at about $26,000. Howard Hughes Medical Institute acquired a new stake in Amgen during the second quarter worth about $32,000. Cloud Capital Management LLC bought a new position in Amgen in the third quarter worth about $34,000. Saranac Partners Ltd acquired a new position in Amgen in the third quarter valued at approximately $37,000. Finally, Holos Integrated Wealth LLC acquired a new position in Amgen in the fourth quarter valued at approximately $37,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AMGN has been the topic of a number of research reports. Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a research report on Saturday, February 21st. Deutsche Bank Aktiengesellschaft upped their price objective on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research note on Thursday, February 5th. UBS Group increased their target price on Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Leerink Partners reiterated a “market perform” rating and issued a $355.00 target price on shares of Amgen in a research note on Thursday, March 5th. Finally, Sanford C. Bernstein lowered shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target for the company. in a research report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $354.60.

Amgen Stock Performance

Shares of AMGN stock opened at $353.93 on Thursday. Amgen Inc. has a 12-month low of $261.43 and a 12-month high of $391.29. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The firm has a market capitalization of $190.79 billion, a price-to-earnings ratio of 24.87, a price-to-earnings-growth ratio of 3.46 and a beta of 0.45. The business has a 50 day simple moving average of $361.76 and a 200 day simple moving average of $329.23.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The firm had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same quarter in the previous year, the business earned $5.31 EPS. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, equities research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 annualized dividend and a yield of 2.8%. Amgen’s dividend payout ratio is presently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.